Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant

NCT06265584 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Acute Leukemia
Myelodysplastic Syndrome
Myeloproliferative Disorders

Interventions

DRUG: ATG dosing platform when combined with standard tacrolimus and mini methotrexate

Sponsor

University of Alabama at Birmingham